Mineralys Therapeutics Reports on Shareholder Votes
Ticker: MLYS · Form: 8-K · Filed: May 22, 2024 · CIK: 1933414
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Mineralys held a shareholder vote meeting on 5/22/24.
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented, but it confirms the date of the event and the company's reporting obligations.
Why It Matters
This filing indicates that Mineralys Therapeutics held a meeting where security holders voted on certain matters, a standard corporate governance event.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding shareholder votes, with no immediate financial or operational impact disclosed.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- May 22, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087 (address) — Principal executive offices
FAQ
What specific matters were submitted for a vote by Mineralys Therapeutics' security holders?
The provided 8-K filing does not specify the exact matters that were submitted for a vote by security holders.
On what date did the event requiring this 8-K filing occur?
The earliest event reported in this filing occurred on May 22, 2024.
What is the principal business address of Mineralys Therapeutics, Inc.?
The principal executive offices of Mineralys Therapeutics, Inc. are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission File Number for Mineralys Therapeutics, Inc.?
The Commission File Number for Mineralys Therapeutics, Inc. is 001-41614.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-05-22 16:38:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20240522.htm (8-K) — 30KB
- 0001933414-24-000017.txt ( ) — 158KB
- mlys-20240522.xsd (EX-101.SCH) — 2KB
- mlys-20240522_lab.xml (EX-101.LAB) — 23KB
- mlys-20240522_pre.xml (EX-101.PRE) — 13KB
- mlys-20240522_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 22, 2024 , Mineralys Therapeutics, Inc. (the Company) held its 2024 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown: Proposal 1 – To elect one director to serve as a Class I director for a three-year term to expire at the 2027 annual meeting of stockholders. Name For Withhold Broker Non-Votes Jon Congleton 26,418,385 3,775,533 1,838,014 Proposal 2 – To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstain Broker Non-Votes 32,025,366 1,187 5,379 0 Both Proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company's common stock. Each Proposal is described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 9, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 22, 2024 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary